Bioiberica, SAU – FDA 483, Sep 13, 2024
An FDA inspection of Bioiberica, SAU's drug substance manufacturing facility in Palafolls, Spain, revealed significant deficiencies. Observations included a lack of quality unit oversight for maintenance, inadequate equipment cleaning leading to material residue, and insufficient review of deviations and out-of-specification results. Additionally, the firm failed to fully validate laboratory test procedures for pyrogens and total microbial limit tests, specifically for endotoxin release testing.
ID · 183571fe-a614-4e7f-82d1-c38d1b9a58b4
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.